1. Home
  2. GCT vs COAG Comparison

GCT vs COAG Comparison

Compare GCT & COAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GCT

GigaCloud Technology Inc

HOLD

Current Price

$33.37

Market Cap

1.7B

ML Signal

HOLD

Logo Hemab Therapeutics Holdings Inc. Common Stock

COAG

Hemab Therapeutics Holdings Inc. Common Stock

N/A

Current Price

$28.76

Market Cap

1.4B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GCT
COAG
Founded
2019
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Catalog/Specialty Distribution
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.4B
IPO Year
2021
2026

Fundamental Metrics

Financial Performance
Metric
GCT
COAG
Price
$33.37
$28.76
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$33.00
N/A
AVG Volume (30 Days)
688.9K
319.5K
Earning Date
05-08-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
17.70
N/A
EPS
1.04
N/A
Revenue
$1,161,042,000.00
N/A
Revenue This Year
$14.43
N/A
Revenue Next Year
$6.78
N/A
P/E Ratio
$32.03
N/A
Revenue Growth
64.96
N/A
52 Week Low
$19.25
$27.83
52 Week High
$51.82
$31.98

Technical Indicators

Market Signals
Indicator
GCT
COAG
Relative Strength Index (RSI) 41.46 N/A
Support Level $25.96 N/A
Resistance Level $34.46 N/A
Average True Range (ATR) 1.49 0.00
MACD 0.33 0.00
Stochastic Oscillator 42.45 0.00

Price Performance

Historical Comparison
GCT
COAG

About GCT GigaCloud Technology Inc

GigaCloud Technology Inc provides end-to-end and B2B e-commerce solutions for large parcel merchandise. Its B2B e-commerce platform, which is referred to as the GigaCloud Marketplace, integrates everything from discovery, payments, and logistics tools into one easy-to-use platform. It offers online and offline integrated cross-border transaction and delivery services for furniture and large merchandise. Its marketplace seamlessly connects manufacturers in Asia with resellers in the U.S., Asia, and Europe to execute cross-border transactions with confidence, speed, and efficiency. It offers a truly comprehensive solution that transports products from the manufacturer's warehouse to end customers, all at one fixed price. It earns the majority of its revenue from the United States.

About COAG Hemab Therapeutics Holdings Inc. Common Stock

Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.

Share on Social Networks: